In mice treated with the DYRK3 inhibitor, there was a slight increase in tumor sizes at certain intervals, resulting in a 1.6 times larger size by the 8th week compared to the control group, a difference that was statistically significant (p < 0.01). This evidence concerns the gene DYRK3 and neoplasm.